RecruitingNAINTERVENTIONAL

MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2

MAPPYACTS 2 is a study helping children and young adults in France with cancer that has returned or is hard to treat. It uses advanced tests to look closely at the cancer's genetic make-up. Based on these insights, a team of experts, including doctors and scientists, discusses and recommends the most suitable experimental treatments or early-stage trials. This study works alongside a program called FMG2025, which performs the tests. MAPPYACTS 2 then translates these test results into practical treatment plans and helps patients access those special treatments. The goal is to learn more about these cancers and find better ways to treat them to improve the lives of young patients.

At a glance

Status

Recruiting

Phase

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Enrolment target

1,800

Start

09 Sep 2022

Estimated completion

09 Sep 2030

Solid Tumor Leukemia

What is this study about?

This study, called MAPPYACTS 2, is looking for better ways to treat cancers in children and young adults, up to the age of 25. Specifically, it's for those whose cancer has either come back after treatment or isn't responding well to standard treatments. It's an international study, with a focus on France, where advanced genetic testing of the cancer is becoming a standard way to help decide on treatment.

The main idea behind MAPPYACTS 2 is to understand each patient's cancer at a very detailed level. Doctors take a sample of the cancer – usually from a biopsy or surgery – and run special tests on it. These tests look at the 'molecular' make-up of the cancer, which means they examine the genes and other tiny parts of the cancer cells. This helps identify what makes each cancer unique.

Once these test results are back, a group of specialists, including doctors, biologists, and scientists, carefully reviews them. They then discuss and recommend personalised treatment options. These often involve experimental treatments or participation in other early-stage clinical trials that might be a better match for that specific cancer based on its unique characteristics. MAPPYACTS 2 also helps patients get access to these trials and collects information to see how well these new approaches work, ultimately aiming to improve cancer care for young patients.

Key takeaways

Targets children and young adults (6-25) with relapsed or hard-to-treat cancer.
Uses advanced genetic tests to understand unique cancer features.
Helps doctors recommend personalised experimental treatments or clinical trials.
Aims to improve cancer care and outcomes for young patients.
Does not involve receiving new medication directly within this study.

Who may be eligible?

This study is for children and young adults, from 6 up to 25 years old, who have a solid tumour or leukaemia that has either returned or isn't getting better with standard treatments. To join, your doctor would need to be able to take a sample of your cancer (like a biopsy or from surgery) within the last three months, or plan to take one soon.

You would need to be seen as healthy enough to take part in another clinical trial afterwards, with a life expectancy of more than three months. Also, you and your family would need to agree to participate by signing consent forms. These forms give permission for your medical information and the results of your cancer tests to be collected and used to help guide treatment decisions and for research.

There are also some reasons why you might not be able to join, such as if you have another illness that might make it hard to understand the study results, or if you are pregnant.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you between 6 and 25 years old?
Do you have a solid tumour or leukaemia that has returned or is hard to treat?
Is it possible to get a recent cancer sample (biopsy, surgery, etc.)?
Are you generally well enough that you could join another clinical trial?
Are you and your guardian (if applicable) willing to sign consent forms?

Answer every question to see your result.

What does participation involve?

If you join this study, the main thing that happens is that a sample of your cancer will be sent for special genetic testing. This is usually done from a biopsy or surgery that you would have anyway. Your medical information, including your cancer diagnosis, past treatments, and how you respond to new treatments, will be collected throughout your care.

After the genetic tests, a team of experts will discuss the results and suggest possible treatment options, which might include specific clinical trials that are best suited to your cancer. You wouldn't be given any new medication directly as part of this study itself. However, the study helps you understand if you might be suitable for specific experimental treatments or trials. The full duration of your participation would depend on your treatment journey and how long the study continues to collect follow-up information on your health.

Potential risks and benefits

A potential benefit of taking part is that the detailed genetic testing of your cancer might help your doctors find a more targeted or effective treatment option for you, especially if standard treatments haven't worked well. This could give you access to experimental treatments or clinical trials that you might not otherwise have known about. There are no direct medical risks from participating in this study itself, as it mainly involves using information from tests you would already have. However, any suggested experimental treatments or trials would have their own specific risks and benefits, which your doctor would discuss with you. You are free to withdraw from the study at any time.

Locations (29)

Gustave Roussy
Verified postcode
Paris, France· Recruiting
CHU Amiens-Picardie
Verified postcode
Amiens, France· Recruiting
CHU Angers
Verified postcode
Angers, France· Recruiting
CHU Besançon
Verified postcode
Besançon, France· Recruiting
CHU Pellegrin
Verified postcode
Bordeaux, France· Recruiting
CHRU Morvan
Verified postcode
Brest, France· Recruiting
CHU de Caen
Verified postcode
Caen, France· Recruiting
CHU Estaing
Verified postcode
Clermont-Ferrand, France· Recruiting
CHU Dijon François Mitterand
Verified postcode
Dijon, France· Recruiting
CHU Grenoble Alpes
Verified postcode
Grenoble, France· Recruiting
Centre Oscar Lambret
Verified postcode
Lille, France· Recruiting
Chu Limoges
Verified postcode
Limoges, France· Recruiting

Common questions

What kind of cancers is this study for?

It's for children and young adults with solid tumours or leukaemia that have come back or are not responding well to standard treatments.

Will I get new medicine through this study?

No, this study doesn't give you medicine directly. It uses special tests to help your doctors find suitable experimental treatments or trials that you might then go on to receive.

How old do I need to be to join?

You need to be between 6 and 25 years old.

What does 'molecular profiling' mean?

It means doing special tests on your cancer cells to look at their unique genetic make-up, like a fingerprint, to understand what drives the cancer.

Is this study only in France?

While it's an international study, its main effort and the program it links with (FMG2025) are based in France.

How to find out more

Birgit GEOERGER, MD

birgit.geoerger@gustaveroussy.fr +33 (0)1 42 11 46 61 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.